This is a non-core endpoint: only basic statistics are computed.
Malignant immunoproliferative diseases
CD2_IMMUNOPROLIFERATIVE
lymphoma: A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
354 |
4. Check minimum number of eventsNone |
354 |
5. Include endpointsNone |
354 |
6. Filter based on genotype QC (FinnGen only) |
337 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF4
- Parent code in ICD-10
- C81-C96
- Name in latin
- Morbi immunoproliferativi maligni
Similar endpoints
↥List of similar endpoints to
Malignant immunoproliferative diseases
based on the number of shared cases.
Similar with more cases:
- Primary_lymphoid and hematopoietic malignant neoplasms
- Liquid cancers, helper endpoint
- Malignant neoplasm
- Malignant neoplasm, wide definition for exclusion
- Neoplasms
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 337 | 135 | 202 |
| Unadjusted period prevalence (%) | 0.07 | 0.05 | 0.09 |
| Median age at first event (years) | 68.80 | 66.52 | 70.32 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 354
- Matched controls
- 3540
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C88.0
ICD-10 Finland
Waldenström macroglobulinaemia
+∞
319.1
256
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
39.2
266.7
198
111
XW000
NOMESCO Finland
Bone marrow biopsy
34.0
232.4
175
99
D47.2
ICD-10 Finland
Monoclonal gammopathy of undetermined significance (MGUS)
71.7
164.4
91
17
9761/3-C42.0
ICD-O-3
Waldenstrom macroglobulinemia of blood
+∞
99.8
91
*
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
37.8
94.3
60
19
R70.0
ICD-10 Finland
Elevated erythrocyte sedimentation rate
22.5
87.8
68
37
L03AA02
ATC
filgrastim; parenteral
15.3
75.8
72
58
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
29.6
74.5
51
20
C88.9
ICD-10 Finland
Malignant immunoproliferative disease, unspecified
+∞
67.9
63
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
15.4
66.5
62
48
A04AA01
ATC
ondansetron; systemic, rectal
7.9
60.2
99
166
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
18.2
50.3
42
26
M04AA01
ATC
allopurinol; systemic
5.0
44.7
133
380
WW500
NOMESCO Finland
Blood transfusion
8.3
43.9
64
92
JN6AD
NOMESCO Finland
CT of torso and neck
17.1
43.2
37
24
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.1
41.3
111
290
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
7.0
40.4
69
118
9671/3-C42.1
ICD-O-3
Lymphoplasmacytic lymphoma of bone marrow
+∞
38.2
36
*
L03AA13
ATC
pegfilgrastim; parenteral
7.8
34.9
52
76
R50.9
ICD-10 Finland
Fever, unspecified
4.5
34.3
109
321
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
7.5
32.4
50
76
C83.80
ICD-10 Finland
B-cell lymphoma in marginal zone
120.9
31.2
33
*
390
Kela drug reimbursment
Ibrutinib
292.1
27.1
27
*
1512
Kela drug reimbursment
Ibrutinib
292.1
27.1
27
*
JN4BD
NOMESCO Finland
Extensive body CT
3.9
25.5
91
286
C88.7
ICD-10 Finland
Other malignant immunoproliferative diseases
+∞
25.3
24
*
JN4AD
NOMESCO Finland
Body CT examination
4.1
24.9
81
238
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
5.7
24.8
50
99
L01EL01
ATC
ibrutinib; oral
+∞
23.2
22
*
D64.9
ICD-10 Finland
Anaemia, unspecified
3.7
22.2
84
273
C85.9
ICD-10 Finland
Non-Hodgkin lymphoma, unspecified
24.1
22.1
31
14
C88.4
ICD-10 Finland
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lyphoma]
+∞
21.0
20
*
L01AA02
ATC
chlorambucil; oral
61.3
20.1
23
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
4.8
19.9
48
111
ZX120
NOMESCO Finland
Intravenous
3.7
19.6
72
228
J05AB11
ATC
valaciclovir; oral
3.3
19.3
89
326
J05AB01
ATC
aciclovir; systemic
3.0
19.1
115
492
B03XA02
ATC
darbepoetin alfa; parenteral
7.2
17.7
27
40
1XC02, ,
NOMESCO Finland
33.4
17.2
22
7
C83.01
ICD-10 Finland
Lymphoplasmacytic lymphoma
178.0
16.6
17
*
H02AB06
ATC
prednisolone; systemic
2.5
16.1
213
1321
H02AB02
ATC
dexamethasone; systemic
3.3
16.0
71
252
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
27.8
15.8
21
8
WW200
NOMESCO Finland
Immunization
6.9
15.1
24
37
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.0
14.9
77
299
N08.1*C88.0
ICD-10 Finland
Glomerular disorders in Waldenström's macroglobulinaemia
+∞
14.7
14
*
R59.0
ICD-10 Finland
Localized enlarged lymph nodes
5.5
14.1
28
54
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
12.2
13.5
24
21
212
Kela drug reimbursment
Gout
6.6
13.4
22
35
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
3.7
13.2
45
134
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.4
13.2
137
745
TPH04
NOMESCO Finland
Cathetrisation of vein
2.5
13.1
110
543
C90.0
ICD-10 Finland
Multiple myeloma
12.9
12.8
22
18
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
27.8
12.1
16
6
A41.9
ICD-10 Finland
Sepsis, unspecified
4.4
11.9
31
76
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.3
11.8
138
782
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.2
11.7
210
1409
C83.3
ICD-10 Finland
Diffuse large B-cell lymphoma
23.8
11.7
16
7
L01XE27
ATC
[U] ibrutinib
123.9
11.5
12
*
R59.1
ICD-10 Finland
Generalized enlarged lymph nodes
11.1
11.4
21
20
B03XA01
ATC
erythropoietin; parenteral
11.7
11.2
20
18
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
4.4
11.1
29
71
JN6BD
NOMESCO Finland
Extensive CT of torso and neck
16.2
10.9
17
11
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
4.7
10.9
26
59
D70.82
ICD-10 Finland
Drug-induced neutropenia
10.1
10.9
21
22
J01MA12
ATC
levofloxacin; systemic
2.4
10.9
96
480
A03FA01
ATC
metoclopramide; systemic, rectal
2.3
10.8
102
525
L01AA01
ATC
cyclophosphamide; systemic
22.3
10.8
15
7
C83.39
ICD-10 Finland
Diffuse non-Hodgkin's large cell lymphoma UNS
61.9
10.7
12
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.4
10.6
91
449
C83.1
ICD-10 Finland
Mantle cell lymphoma
19.5
10.3
15
8
C85.1
ICD-10 Finland
B-cell lymphoma, unspecified
41.3
10.0
12
*
B02.9
ICD-10 Finland
Zoster without complication
3.1
9.9
44
155
C83.9
ICD-10 Finland
Non-follicular (diffuse) lymphoma, unspecified
26.9
9.9
13
5
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
18.2
9.5
14
8
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
7.3
9.5
22
32
WZC00
NOMESCO Finland
Treatment plan or consultation
2.0
9.4
140
857
PJ2AT
NOMESCO Finland
Biopsy of lymphnode with ultrasound guidance
37.7
9.1
11
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
2.9
9.0
45
169
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
7.5
8.9
20
28
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
3.4
8.7
33
105
J01MA14
ATC
moxifloxacin; systemic
2.7
8.6
50
204
L03AA14
ATC
lipegfilgrastim; parenteral
7.7
8.6
19
26
9689/3-C42.2
ICD-O-3
Splenic marginal zone B-cell lymphoma of spleen
+∞
8.4
8
*
A02BC02
ATC
pantoprazole; systemic
2.1
8.2
261
2041
ZX108
NOMESCO Finland
Inhalation
12.1
8.1
14
12
TAB00
NOMESCO Finland
Lumbar puncture
3.6
8.1
27
79
127
Kela drug reimbursment
Transplant complication
8.1
8.0
17
22
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
8.8
7.9
16
19
NJ3DA
NOMESCO Finland
Long bones of extremities X-ray examination
15.5
7.8
12
8
L04AA06
ATC
mycophenolic acid; systemic
7.7
7.8
17
23
9591/3-C42.1
ICD-O-3
Malignant lymphoma, non-Hodgkin, NOS, of bone marrow
46.0
7.7
9
*
WW300
NOMESCO Finland
Transfer of autologic stem cells
18.9
7.6
11
6
XW4XT
NOMESCO Finland
Biopsy of other inner organ with radiological guidance guidance
25.6
7.6
10
*
PJD41
NOMESCO Finland
Excision of cervical lymph nodes
7.4
7.6
17
24
C03CA01
ATC
furosemide; systemic
1.9
7.4
154
1034
ZXE00
NOMESCO Finland
One hour or less
1.9
7.3
144
951
D70.89
ICD-10 Finland
Neutropenic splenomegaly
7.6
7.3
16
22
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
7.6
7.3
16
22
ZX112
NOMESCO Finland
Subcutaneous
4.4
7.1
18
43
JN3AD
NOMESCO Finland
Abdominal CT examination
2.4
7.0
52
238
Z01.8
ICD-10 Finland
Other specified special examinations
2.0
7.0
91
522
GD1AD
NOMESCO Finland
Thorax CT examination
2.9
6.7
31
112
TDM10
NOMESCO Finland
Puncture of maxillary antrum
4.0
6.6
19
50
EN1AD
NOMESCO Finland
CT examination of mouth and soft tissues of neck
12.6
6.6
11
9
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
2.7
6.6
36
142
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
7.1
6.6
15
22
C82.01
ICD-10 Finland
Follicular nodular lymphoma, grade I
71.1
6.4
7
*
D80.1
ICD-10 Finland
Nonfamilial hypogammaglobulinaemia
71.1
6.4
7
*
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
14.6
6.4
10
7
A04AA02
ATC
granisetron; systemic, transdermal
2.8
6.4
33
126
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
6.8
6.4
15
23
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
4.0
6.3
18
47
WX408
NOMESCO Finland
General anesthesy, balanced
1.9
6.3
103
635
C88.3
ICD-10 Finland
Immunoproliferative small intestinal disease
+∞
6.3
6
*
C82.00
ICD-10 Finland
Follicular nodular non-Hodgkin's lymphoma, ungraded
+∞
6.3
6
*
L01BB05
ATC
fludarabine; systemic
27.2
6.3
8
*
N02AA05
ATC
oxycodone; systemic
1.9
6.2
89
526
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
3.2
6.2
24
78
ZXE10
NOMESCO Finland
More than one and less than three hours
1.8
6.1
137
929
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
3.4
6.1
22
68
JN3BD
NOMESCO Finland
Extensive abdominal CT
2.3
6.1
46
212
J01CA04
ATC
amoxicillin; systemic
1.9
6.0
276
2297
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
228
191
31.73
253.73
11.7
1.4
13.89
1.13
g/l
32.14
219
171
177
111
30.89
224.21
7.1
3.4
116.45
121.19
mg/l
0.03
150
89
177
111
30.89
224.21
7.0
3.4
29.79
36.61
mg/l
0.67
150
91
175
109
30.77
222.21
7.1
3.3
8.26
2.54
ratio
—
8
11
255
398
20.33
185.65
9.9
4.2
224.91
241.77
u/l
1.23
247
376
195
236
17.17
166.91
5.7
2.4
7.72
10.37
g/l
7.23
190
211
147
119
20.42
160.15
9.8
2.4
8.04
0.65
g/l
12.37
125
106
119
72
24.39
149.48
1.5
1.7
—
—
—
0
0
148
142
17.19
145.16
9.2
2.1
3.73
3.53
g/l
0.32
143
129
148
142
17.19
145.16
9.3
2.1
7.00
7.41
g/l
1.65
143
129
148
142
17.19
145.16
9.2
2.1
—
—
—
0
0
137
134
16.05
131.89
9.7
2.2
2.74
3.05
g/l
1.98
132
121
132
130
15.60
126.15
9.5
2.2
15.13
10.43
g/l
5.08
123
116
112
96
16.60
115.87
2.5
1.6
—
—
—
0
0
192
416
8.90
96.46
5.6
2.7
1.69
1.81
%
0.75
181
378
162
315
8.64
89.01
5.1
2.7
65.59
67.71
e9/l
0.27
133
240
120
165
10.49
88.53
2.8
2.2
1.49
1.53
g/l
0.15
106
145
102
116
11.95
86.58
10.0
2.3
37.42
37.22
g/l
0.10
93
103
50
21
27.56
71.20
1.5
1.1
—
—
—
0
0
182
509
6.30
66.45
3.7
1.3
1.29
2.77
g/l
13.14
161
301
66
61
13.07
63.59
7.3
8.0
829.67
151.75
iu/ml
—
9
12
219
819
5.39
54.48
7.0
3.0
1450.86
9031.05
umol/l
2.71
209
699
46
31
16.91
52.89
2.0
2.7
—
—
—
0
0
281
1337
6.34
50.73
14.1
5.9
55.05
58.01
%
3.36
273
1256
37
20
20.54
47.15
2.0
1.6
—
—
—
0
0
37
20
20.54
47.15
2.0
1.6
—
—
—
0
0
141
431
4.78
43.42
11.6
6.1
1.05
1.03
mmol/l
0.30
135
398
301
1664
6.40
41.32
26.9
9.5
3.56
4.22
e9/l
3.67
277
1461
288
1574
5.45
39.02
18.5
7.3
1.22
1.21
mmol/l
0.35
247
1338
52
83
7.17
32.20
2.8
1.7
—
—
—
0
0
43
63
7.63
28.67
2.5
1.8
—
—
—
0
0
257
1468
3.74
28.32
17.2
6.8
1.22
1.21
mmol/l
0.97
252
1321
177
807
3.39
28.22
2.9
2.1
3.23
3.11
mg/l
0.25
155
691
48
82
6.62
27.77
3.5
1.8
—
—
—
0
0
41
59
7.73
27.75
2.6
1.8
—
—
—
0
0
41
59
7.73
27.75
2.6
1.8
—
—
—
0
0
125
479
3.49
26.07
3.8
2.5
24.17
22.51
%
0.59
114
413
134
539
3.39
25.81
8.3
3.8
0.80
0.81
mmol/l
0.65
127
510
33
40
9.00
25.66
2.5
2.0
33.18
33.03
pg
0.08
33
40
41
66
6.89
25.03
1.3
1.4
—
—
—
0
0
125
494
3.37
24.61
3.7
2.5
1.99
2.26
g/l
4.87
120
451
213
1149
3.14
24.45
4.8
2.7
234.56
156.62
ug/l
1.88
205
1038
38
61
6.86
23.23
2.2
1.6
—
—
—
0
0
131
549
3.20
23.19
4.4
2.1
31.22
29.82
s
1.33
124
529
29
37
8.45
21.59
1.8
1.9
—
—
—
0
0
32
47
7.39
21.16
2.1
1.5
—
—
—
0
0
28
36
8.36
20.70
2.4
1.8
—
—
—
0
0
28
36
8.36
20.70
2.4
1.8
—
—
—
0
0
28
36
8.36
20.70
2.4
1.8
—
—
—
0
0
33
52
6.90
20.47
1.8
1.6
—
—
—
0
0
29
40
7.81
20.23
2.3
2.1
—
—
—
0
0
74
239
3.65
19.59
2.7
1.7
—
—
—
0
0
51
128
4.49
19.09
1.6
2.3
40.23
38.85
u/l
0.14
44
115
33
56
6.40
19.06
1.7
1.2
—
—
—
0
0
30
46
7.03
19.06
2.4
1.6
—
—
—
0
0
29
43
7.26
18.98
2.4
2.0
—
—
—
0
0
31
22
15.32
18.96
1.7
2.2
—
—
—
0
0
126
572
2.87
18.71
3.0
1.9
—
—
—
0
0
31
52
6.44
18.09
2.4
1.6
—
—
—
0
0
23
8
30.61
17.64
1.4
1.7
—
—
—
0
0
31
56
5.97
16.80
2.2
1.6
—
—
—
0
0
182
1047
2.52
16.23
6.5
3.5
2.35
2.35
mmol/l
0.05
163
915
207
1276
2.50
15.72
24.8
10.0
0.00
0.00
e9/l
0.25
181
1049
30
57
5.66
15.42
1.5
1.3
7.64
21.69
e6/l
0.50
22
42
30
57
5.66
15.42
1.6
1.4
132.86
2166.34
e6/l
0.50
22
44
28
52
5.76
14.72
1.8
1.2
282.94
304.50
u/ml
0.08
16
26
293
2175
3.01
14.50
7.9
4.3
45.83
13.57
mm/h
30.94
278
1978
28
54
5.54
14.15
5.4
3.0
54.46
59.67
%
0.87
28
54
46
135
3.77
13.83
3.1
2.9
—
—
—
0
0
27
52
5.54
13.66
4.4
2.4
2.98
4.76
e9/l
4.24
27
52
23
38
6.40
13.57
2.4
1.7
—
—
—
0
0
48
151
3.52
13.01
2.7
1.8
3.36
3.76
ug/l
0.06
43
133
23
21
11.63
12.72
2.7
3.0
36.67
42.69
%
0.51
12
13
18
9
20.98
12.58
1.0
1.6
—
—
—
0
0
186
1169
2.25
12.52
4.8
3.5
—
—
—
0
0
206
1364
2.22
12.01
5.7
2.8
—
—
—
0
0
123
662
2.31
11.92
1.9
1.7
1144.69
1207.70
nmol/l
0.29
97
502
22
40
5.80
11.79
2.5
1.7
—
—
—
0
0
22
40
5.80
11.79
2.5
1.7
—
—
—
0
0
63
248
2.87
11.71
4.3
4.1
95.27
85.22
ng/l
0.32
56
224
86
402
2.50
11.36
2.6
1.9
—
—
—
0
0
86
404
2.49
11.23
2.7
1.9
—
—
—
0
0
141
825
2.18
10.98
2.0
1.6
22.58
20.52
nmol/l
0.58
128
689
130
741
2.19
10.77
6.1
2.6
—
—
—
0
0
17
12
14.81
10.59
4.7
1.3
—
—
—
0
0
34
99
3.69
10.30
1.8
1.4
—
—
—
0
0
19
20
9.97
9.89
2.7
2.0
—
—
—
0
0
19
20
9.97
9.89
2.7
2.0
—
—
—
0
0
31
88
3.76
9.74
1.5
1.5
—
—
—
0
0
112
624
2.16
9.66
4.9
3.2
2.52
2.46
mmol/l
4.49
100
554
168
1092
2.02
9.55
3.8
3.5
1751.33
1524.21
ng/l
0.27
150
946
19
22
9.06
9.41
1.3
1.2
—
—
—
0
0
19
24
8.30
8.97
4.5
1.7
—
—
—
0
0
190
1314
1.96
8.82
2.6
2.1
94.34
92.39
pmol/l
0.20
119
692
12
6
20.63
8.52
1.4
3.8
—
—
—
0
0
8
0
+∞
8.36
1.5
0.0
—
—
—
0
0
13
9
14.93
8.26
1.1
1.3
—
—
—
0
0
16
18
9.25
8.12
2.9
2.0
—
—
—
0
0
16
18
9.25
8.12
2.9
2.0
—
—
—
0
0
16
19
8.76
7.90
2.9
1.9
—
—
—
0
0
141
912
1.91
7.72
4.7
3.4
0.64
0.45
e6/l
0.35
117
696
32
109
3.13
7.61
2.2
1.2
—
—
—
0
0
16
21
7.92
7.47
4.3
4.6
—
—
—
0
0
16
21
7.92
7.47
2.1
1.6
—
—
—
0
0
25
74
3.56
7.39
1.6
1.5
—
—
—
0
0
113
689
1.94
7.32
3.9
2.7
3.27
4.00
e6/l
0.70
101
623
168
1164
1.84
7.31
3.0
2.3
82.77
78.30
nmol/l
0.92
155
1012
11
7
16.15
7.27
1.3
1.1
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
36
135
2.86
7.25
6.3
3.3
0.29
0.37
u/ml
0.99
17
71
15
19
8.19
7.18
1.1
1.0
—
—
—
0
0
14
17
8.52
6.89
2.3
1.6
—
—
—
0
0
212
1595
1.82
6.89
17.7
16.9
1.22
1.33
inr
1.39
67
426
105
638
1.92
6.80
3.0
1.8
2.31
1.36
mg/l
0.53
91
502
65
333
2.17
6.73
10.4
4.0
2.31
1.82
mmol/l
0.50
54
275
14
18
8.05
6.67
2.3
1.6
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
10
7
14.65
6.43
2.9
1.1
153.40
133.43
%
—
10
7
104
649
1.85
6.12
4.1
4.1
1010.06
307.12
ng/l
0.45
87
555
12
14
8.83
6.10
5.4
1.6
96.92
93.64
%
0.11
12
14
14
21
6.89
6.09
1.2
1.0
—
—
—
0
0
95
579
1.88
6.01
3.9
3.0
1.53
1.11
e6/l
0.31
64
338
245
1967
1.80
5.99
6.4
4.8
430.20
3765.11
e6/l
—
5
36
24
80
3.15
5.92
2.0
1.5
8.36
0.16
iu/ml
—
6
20
17
45
3.92
5.88
1.5
1.3
—
—
—
0
0
16
41
4.04
5.78
5.0
4.4
—
—
—
0
0
34
140
2.58
5.74
3.7
1.9
—
—
—
0
0
15
28
5.55
5.60
1.2
1.1
—
—
—
0
0
14
24
6.03
5.58
2.9
1.5
—
—
—
0
0
20
62
3.36
5.54
1.8
1.4
—
—
—
0
0
20
62
3.36
5.54
1.8
1.4
—
—
—
0
0
70
400
1.93
5.33
1.3
1.3
4.40
14.06
u/ml
1.21
23
145
16
44
3.76
5.26
3.1
1.6
—
—
—
0
0
16
44
3.76
5.26
1.9
1.3
709.00
1848.76
e6/l
1.48
11
29
137
962
1.69
5.23
3.9
2.5
60.68
62.63
u/l
0.11
128
890
5
0
+∞
5.22
1.2
0.0
—
—
—
0
0
73
428
1.89
5.14
1.4
1.3
49.26
38.16
iu/ml
0.15
19
140
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
8
6
13.60
5.10
1.0
1.2
96.50
115.00
%
—
8
6
87
543
1.80
5.01
4.2
3.3
1.76
1.59
e6/l
0.12
56
306
11
16
7.06
4.99
1.3
1.2
—
—
—
0
0
16
46
3.60
4.95
3.1
1.5
—
—
—
0
0
16
46
3.60
4.95
3.1
1.5
—
—
—
0
0
8
7
11.65
4.80
2.3
1.4
—
—
—
0
0
14
30
4.81
4.73
1.1
1.1
—
—
—
0
0
63
363
1.89
4.66
2.8
4.3
8.41
44.49
ug/l
0.92
44
309
12
22
5.61
4.64
2.4
1.3
—
—
—
0
0
7
5
14.24
4.59
1.6
1.6
—
—
—
0
0
23
88
2.73
4.49
1.6
2.3
—
—
—
0
0
59
338
1.89
4.44
5.3
3.7
—
—
—
0
0
9
12
7.66
4.38
1.1
1.1
—
—
—
0
0
20
73
2.84
4.26
3.4
2.3
115.07
125.53
g/l
0.64
14
51
15
46
3.36
4.23
3.3
1.5
—
—
—
0
0
15
46
3.36
4.23
3.3
1.5
—
—
—
0
0
54
306
1.90
4.19
12.9
9.0
1.41
1.40
mmol/l
0.01
54
298
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
9
13
7.07
4.18
1.3
1.1
—
—
—
0
0
13
30
4.46
4.17
1.1
1.1
—
—
—
0
0
10
17
6.02
4.16
1.5
1.0
—
—
—
0
0
15
47
3.29
4.10
3.3
1.5
—
—
—
0
0
8
10
8.15
4.08
1.0
1.0
—
—
—
0
0
8
10
8.15
4.08
1.3
1.0
—
—
—
0
0
181
1424
1.55
4.05
4.6
3.9
0.00
0.00
estimate
0.50
37
284
11
22
5.12
4.03
2.5
1.3
—
—
—
0
0
313
2824
1.94
3.92
45.6
17.0
24.05
25.42
mg/l
0.36
296
2287
11
23
4.90
3.90
1.2
1.1
—
—
—
0
0
43
231
1.98
3.90
2.1
1.7
—
—
—
0
0
53
306
1.86
3.89
3.0
2.3
0.16
0.21
g/l
3.89
43
280
6
5
12.17
3.77
1.0
1.0
—
—
—
0
0
179
1420
1.53
3.76
6.2
5.1
0.00
0.00
estimate
-0.00
35
262
15
50
3.09
3.73
1.2
1.0
—
—
—
0
0
181
1442
1.52
3.71
4.6
3.9
0.00
0.00
estimate
-0.00
35
251
13
35
3.82
3.63
5.2
2.6
—
—
—
0
0
7
9
7.91
3.57
1.1
1.0
—
—
—
0
0
49
285
1.83
3.51
3.6
2.5
39.43
34.70
u/l
0.13
40
243
8
14
5.82
3.36
1.0
1.2
—
—
—
0
0
161
1272
1.49
3.32
5.5
4.2
55.75
43.07
ng/l
0.38
131
986
9
19
4.83
3.26
2.4
1.3
—
—
—
0
0
9
19
4.83
3.26
2.4
1.3
—
—
—
0
0
124
940
1.49
3.09
4.7
3.1
33.02
34.03
u/l
0.11
117
896
62
401
1.66
3.08
10.2
8.7
1.03
1.15
mmol/l
0.09
50
319
7
12
5.93
3.03
4.1
7.3
—
—
—
0
0
37
207
1.88
3.00
1.9
1.4
—
—
—
0
0
46
277
1.76
2.96
2.8
1.9
342.67
385.96
nmol/l
0.84
46
253
7
13
5.47
2.88
1.7
1.2
—
—
—
0
0
17
71
2.46
2.84
1.6
1.3
—
—
—
0
0
25
124
2.09
2.84
3.1
1.7
—
—
—
0
0
5
6
8.43
2.75
2.0
1.0
99.40
66.67
%
—
5
6
7
14
5.08
2.74
9.7
4.4
175.00
229.64
u/l
—
7
14
6
10
6.08
2.71
1.7
1.5
—
—
—
0
0
7
16
4.44
2.48
1.3
1.3
—
—
—
0
0
8
22
3.70
2.37
2.9
1.5
—
—
—
0
0
7
17
4.18
2.37
1.6
1.2
—
—
—
0
0
7
17
4.18
2.37
1.6
1.2
—
—
—
0
0
201
1723
1.39
2.36
5.7
3.2
58.76
56.98
u/l
0.10
185
1581
30
172
1.81
2.29
4.1
3.4
25.04
24.79
mmol/l
0.12
30
167
48
315
1.61
2.26
2.7
2.8
13.65
7.05
ug/l
0.35
41
277
39
243
1.68
2.25
1.7
1.7
1.72
1.64
%
0.23
32
205
16
75
2.19
2.12
3.1
1.5
—
—
—
0
0
31
185
1.74
2.09
14.1
12.8
24.39
24.54
mmol/l
0.11
31
180
167
1419
1.33
1.95
3.1
2.4
—
—
—
0
0
5
11
4.59
1.94
1.0
1.0
—
—
—
0
0
119
965
1.35
1.88
2.2
2.1
108.21
296.95
u/l
1.72
112
902
15
73
2.10
1.83
1.9
1.6
—
—
—
0
0
13
61
2.17
1.73
1.2
1.2
—
—
—
0
0
36
238
1.57
1.68
2.5
2.8
45.94
61.23
ml/min/173m2
1.78
17
102
5
14
3.61
1.62
1.2
1.1
96.80
115.51
u/l
—
5
14
5
14
3.61
1.62
1.2
1.1
31.40
43.76
u/l
—
5
14
16
87
1.88
1.48
1.6
1.2
—
—
—
0
0
16
87
1.88
1.48
1.6
1.2
—
—
—
0
0
228
2075
1.28
1.40
3.9
3.7
14.63
15.01
pmol/l
1.52
201
1821
313
2979
1.44
1.38
46.1
20.3
91.68
83.45
umol/l
1.38
313
2979
5
19
2.65
1.22
1.6
1.2
—
—
—
0
0
312
2982
1.39
1.20
47.3
20.5
4.00
4.01
mmol/l
0.43
307
2898
6
26
2.33
1.19
1.2
1.0
272.83
236.43
ng/l
—
6
14
6
26
2.33
1.19
1.2
1.0
34.67
36.86
ng/l
—
6
12
6
26
2.33
1.19
1.2
1.0
854.33
538.53
ng/l
—
6
15
19
120
1.62
1.11
1.6
1.3
—
—
—
0
0
126
1095
1.23
1.09
5.1
4.1
—
—
—
0
0
7
32
2.21
1.08
1.1
1.4
0.56
0.48
nmol/l
—
7
27
63
770
0.78
1.02
1.9
1.6
1.44
1.32
mmol/l
0.23
56
632
66
544
1.26
0.91
1.3
1.2
0.51
1.11
u/ml
—
9
144
5
101
0.49
0.91
1.0
1.6
—
—
—
0
0
9
152
0.58
0.91
1.8
1.8
—
—
—
0
0
82
694
1.24
0.90
1.5
1.8
472.47
443.24
pmol/l
0.40
66
563
8
44
1.84
0.86
1.9
1.0
—
—
—
0
0
154
1394
1.19
0.84
4.6
5.5
1.85
2.70
ug/l
1.68
135
1238
6
32
1.89
0.82
1.8
2.1
—
—
—
0
0
7
38
1.86
0.74
1.0
1.1
—
—
—
0
0
5
26
1.94
0.71
1.0
1.1
—
—
—
0
0
270
2582
1.19
0.70
4.7
4.6
2.02
2.00
mu/l
0.05
248
2293
7
42
1.68
0.68
2.6
2.7
2.79
7.48
nmol/l
—
7
42
278
2670
1.19
0.66
36.1
16.0
74.14
74.56
ml/min/173m2
0.11
251
2237
8
51
1.58
0.61
1.4
1.2
—
—
—
0
0
260
2701
0.86
0.59
5.9
6.5
39.21
40.83
mmol/mol
2.37
236
2472
314
3062
1.23
0.55
62.6
24.8
234.06
239.07
e9/l
0.49
308
2973
314
3062
1.23
0.55
63.8
25.2
36.33
39.85
%
18.48
300
2830
314
3063
1.22
0.54
62.6
24.8
3.97
4.45
e12/l
32.93
306
2964
29
233
1.27
0.53
1.1
1.4
—
—
—
0
0
9
63
1.44
0.52
1.1
1.3
—
—
—
0
0
110
1003
1.14
0.52
4.4
3.9
17.41
8.99
mg/mmol
0.79
76
641
10
68
1.48
0.47
1.1
1.1
—
—
—
0
0
5
32
1.57
0.42
1.0
1.5
—
—
—
0
0
86
786
1.12
0.39
5.9
4.2
0.00
0.00
estimate
-0.00
30
253
118
1111
1.09
0.31
4.1
4.7
21.82
21.08
%
0.18
59
561
68
624
1.11
0.30
5.3
4.4
1.02
1.02
kg/l
0.76
11
92
8
65
1.24
0.27
1.0
1.2
—
17.20
—
0
6
43
393
1.11
0.21
16.1
8.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.8
—
62.03
—
0
11
0
10
0.00
0.21
0.0
1.0
—
5.83
—
0
10
0
14
0.00
0.20
0.0
1.1
—
354.57
—
0
7
11
90
1.23
0.19
1.3
1.3
—
—
—
0
0
272
2759
0.94
0.17
4.3
4.8
4.16
4.46
mmol/l
4.64
248
2503
282
2786
1.06
0.14
5.0
5.1
5.96
6.11
mmol/l
1.40
250
2500
280
2832
0.95
0.13
4.8
5.5
2.32
2.60
mmol/l
6.89
255
2549
30
324
0.92
0.13
1.3
1.4
—
—
—
0
0
271
2741
0.95
0.12
4.3
4.8
1.37
1.43
mmol/l
1.34
245
2465
10
116
0.86
0.12
1.0
1.0
—
—
—
0
0
5
47
1.06
0.09
1.8
1.5
33.96
17.46
ug/l
—
5
47
14
128
1.10
0.07
1.0
1.1
26.04
137.72
iu/ml
—
5
46
26
250
1.04
0.03
1.8
2.2
12.14
12.77
nmol/l
0.18
26
220
266
2657
1.00
0.00
4.1
4.3
1.20
1.28
mmol/l
0.69
238
2375
81
807
1.00
0.00
2.8
3.2
0.67
0.76
ug/l
0.66
58
562
41
405
1.01
0.00
4.4
4.8
31.97
31.60
%
0.08
32
262
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
3.5
—
96.52
—
0
6
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
7
78
0.90
-0.00
2.0
1.7
35.29
45.32
nmol/l
—
7
71
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_IMMUNOPROLIFERATIVE – Malignant immunoproliferative diseases
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).